Company Overview of Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. operates as a research-based pharmaceutical company that discovers, develops, and commercializes pharmaceutical products. It offers olmesartan medoxomil, hydrochlorothiazide, prasugrel, cevimeline HCI, amlodipine, colesevelam HCI, and vemurafenib tablets. The company provides therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma areas. It serves patients, and professional organizations and institutions in the United States and internationally. Daiichi Sankyo, Inc. was formerly known as Sankyo Pharma Inc. and changed its name to Daiichi Sankyo, Inc. in April 2006. The company was founded in 1996 and is based in Parsippany, New...
Two Hilton Court
Parsippany, NJ 07054
Founded in 1996
Key Executives for Daiichi Sankyo, Inc.
Executive Chairman, President, Global Head of Research & Development - Daiichi Sankyo Ltd and Senior Executive Officer of Daiichi Sankyo Ltd
Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co., Ltd. and President of Daiichi Sankyo Co., Ltd.
President of Commercial Operations
Executive Vice President and Head of Global Business Development
Compensation as of Fiscal Year 2015.
Daiichi Sankyo, Inc. Key Developments
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints
Oct 29 15
Charleston Laboratories, Inc., and Daiichi Sankyo, Inc. announced that a third Phase 3 clinical trial of CL-108, an opioid-containing formulation, met its primary endpoints. CL-108 is a bi-layered tablet containing 7.5 mg of hydrocodone and 325 mg of acetaminophen uniquely formulated with 12.5 mg of rapid-release promethazine. This novel formulation is being developed as a treatment for moderate to severe pain and the prevention of opioid-induced nausea and vomiting (OINV). This recently completed Phase 3 clinical trial was a randomized, double-blind, placebo- and active-controlled study in over 550 patients in the U.S. who experienced moderate to severe pain after bunionectomy surgery. Results from the study demonstrated significant pain relief and prevention of OINV by CL-108.
Daiichi Sankyo, Inc. Reorganizes U.S. Commercial Operations to Support Upcoming Specialty Pipeline; to Eliminate 1,000 to 1,200 Positions
Oct 16 15
Daiichi Sankyo, Inc. announced that it will reorganize its U.S. Commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology. Daiichi Sankyo recognizes the macro changes occurring in the U.S. healthcare system that place a greater emphasis on managing the needs of patients with more complex healthcare needs.
As part of the reorganization, the Company will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations. The Company expects to eliminate 1,000 to 1,200 positions across the U.S. Commercial function, through voluntary and involuntary displacements as well as eliminating open positions. The eliminated jobs will come from the U.S. Commercial Home Office, located in Parsippany, New Jersey, as well as field-based sales and other positions throughout the country. This reorganization is not focused on U.S.-based R&D functions, which have staff concentrated in Edison, NJ, or its packaging plant in Bethlehem, PA.
Daiichi Sankyo, Inc. Reports Revenue Results for the First Quarter of Fiscal 2016; Revised Revenue Guidance for Fiscal 2016
Jul 31 15
Daiichi Sankyo, Inc. reported revenue results for the first quarter of fiscal 2016. Revenue was JPY 48.0 billion against JPY 41.6 billion last year.
The company revised revenue guidance for fiscal 2016. The company expects revenue of JPY 166.0 billion against previous guidance of JPY 140.0 billion.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|